Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252019 | 1.00 | PDE4B (0.57) | PDE4BHDAC1HDAC2RORCSLC6A3 | |
| SCHEMBL4252028 | 1.00 | PDE4B (0.57) | PDE4BHDAC1HDAC2RORCSLC6A3 | |
| SCHEMBL3002077 | 1.00 | PDE4B (0.57) | PDE4BHDAC1HDAC2RORCSLC6A3 | |
| SCHEMBL951753 | 0.91 | PDE4B (0.57) | PDE4BSLC6A3SLC6A4TACR1SLC6A2 | |
| SCHEMBL16108580 | 0.91 | PDE4B (0.57) | PDE4BSLC6A3SLC6A4TACR1SLC6A2 | |
| SCHEMBL16108582 | 0.91 | PDE4B (0.57) | PDE4BSLC6A3SLC6A4TACR1SLC6A2 | |
| SCHEMBL18244756 | 0.91 | PDE4B (0.57) | PDE4BSLC6A3SLC6A4TACR1SLC6A2 | |
| SCHEMBL23951690 | 0.90 | PDE4B (0.70) | PDE4BHDAC1HDAC2RORCSLC6A3 | |
| SCHEMBL4006266 | 0.90 | PDE4B (0.70) | PDE4BHDAC1HDAC2RORCSLC6A3 | |
| SCHEMBL14498543 | 0.90 | PDE4B (0.70) | PDE4BHDAC1HDAC2RORCSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391615-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-01-16 | — | — | EP | disclosed |
| EP-2391615-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-8324248-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324248-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324248-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2391615-A1 | Piperidine derivatives as nk3 receptor antagonists | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20100197697-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | US | disclosed |
| US-20100197697-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | US | disclosed |
| US-20100197697-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | US | disclosed |
| WO-2010086259-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086259-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1789389-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006030984-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197697-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRK1, OPRM1, OPRL1 | PDE4B 1062/4885HDAC1 2173/4885HDAC2 2706/4885 |
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | AVPR1B, PRLHR, HRH4 | PDE4B 1273/4885HDAC1 671/4885HDAC2 321/4885 |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | AVPR1B, HRH4, PRLHR | PDE4B 1656/4885HDAC1 512/4885HDAC2 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.